Literature DB >> 14601763

Sequential conditional probability ratio tests for normalized test statistic on information time.

Xiaoping Xiong1, Ming Tan, James Boyett.   

Abstract

Sequential conditional probability ratio tests (SCPRTs) provide monitoring procedures with a unique property that a decision reached at early stopping is unlikely to be reversed should the trial continue to the planned end (Xiong, X., 1995, Journal of the American Statistical Association 90, 1463-1473; Tan, M., Xiong, X., and Kutner, M. H., 1998, Biometrics 54, 682-95). It actually provides a probability statement of a conclusion reversal, should the proposed interim analysis plan be used. To broaden its scope of applications, in this article we develop the SCPRT in terms of Brownian motion, which is applicable to most clinical trials with various endpoints. In addition, we utilize the unique structure of the SCPRT to derive a class of adaptive sequential tests that retain the significance level and power in the presence of a nuisance parameter. We illustrate the proposed methods with examples in clinical trials.

Mesh:

Year:  2003        PMID: 14601763     DOI: 10.1111/1541-0420.00072

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  6 in total

1.  Survival trial design and monitoring using historical controls.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Pharm Stat       Date:  2016-06-15       Impact factor: 1.894

2.  A sequential conditional probability ratio test procedure for comparing diagnostic tests.

Authors:  Liansheng Tang; Ming Tan; Xiao-Hua Zhou
Journal:  J Appl Stat       Date:  2010-10-01       Impact factor: 1.404

3.  Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity.

Authors:  Ibrahim Qaddoumi; Catherine A Billups; Michael Tagen; Clinton F Stewart; Jianrong Wu; Kathleen Helton; M Beth McCarville; Thomas E Merchant; Rachel Brennan; Tammy M Free; Vicki Given; Barrett G Haik; Carlos Rodriguez-Galindo; Matthew W Wilson
Journal:  Cancer       Date:  2012-04-19       Impact factor: 6.860

4.  Group Sequential Design for Randomized Phase III Trials under the Weibull Model.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  J Biopharm Stat       Date:  2014-10-16       Impact factor: 1.051

5.  Single-Arm Phase II Group Sequential Trial Design with Survival Endpoint at a Fixed Time Point.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Stat Biopharm Res       Date:  2014-05-27       Impact factor: 1.452

6.  Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Stat Biopharm Res       Date:  2017-03-02       Impact factor: 1.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.